```html Magnesium Bioavailability & Clinical Evidence Simulator
Mg

Magnesium Bioavailability & Clinical Evidence Simulator

Pharmacokinetic modeling, transcellular TRPM6/7 fluxes & trial meta-analysis
Physiological PK Engine v2.4
NIH / EFSA Calibrated

Regimen & Patient Baseline

Bisglycinate
14.1% Elemental Mg
200 mg
50 mg 350 mg (Adult UL) 600 mg
240 mg/day
Deficient (<250) Adequate (320-420) Optimal (>420)
Physiological Modulators

Pharmacokinetic Simulator & Physiological Flux

Optimal Bioavailability
Estimated GI Absorption 44.8% ~89.6 mg absorbed
CNS / BBB Uptake Index 1.4x Moderate Neurological Flux
GI Osmotic Load Risk Low (12/100) Minimal loose stool potential
Clinical Effect Size d = 0.58 Moderate Improvement
Dynamic 24-Hour Plasma & CSF Magnesium Concentration Delta
Serum Δ (mg/dL)
CSF / Brain Tissue (Relative)
Osmotic Threshold
Osmotic Distress Threshold 0h (Dose) 4h (Tmax) 8h 12h 16h 20h 24h Cmax: +0.28 mg/dL
Intestinal Transport Partition 68% Active / 32% Passive
■ TRPM6/7 Saturable Channels ■ Paracellular Claudin Flux
Ligand Bio-Activity Glycine (2 Moles)

Glycine functions as an inhibitory neurotransmitter at NMDA receptors and supports core temperature reduction, synergizing with magnesium for sleep latency.

Randomized Controlled Trial (RCT) Evidence Syntheses

Compiled clinical trial endpoints across sleep, migraine prophylaxis, and stress. Baseline deficiency dictates magnitude of effect.

Study & Citation Sample (N) & Population Intervention & Dose Primary Endpoint Observed Standardized Effect (Forest Plot) Key Response Modifiers
*Cohen's d: 0.2 (small), 0.5 (medium), 0.8+ (large). Error bars represent 95% Confidence Intervals from published peer-reviewed meta-analyses.